TSWM
AVIR icon

Tyler-Stone Wealth Management’s Atea Pharmaceuticals AVIR Stock Holding History

Tyler-Stone Wealth Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-154
Closed -$1K – 861
2022
Q3 		$1K Hold
154
– – ﹤0.01% 779
2022
Q2 		$1K Hold
154
– – ﹤0.01% 791
2022
Q1 		$1K Hold
154
– – ﹤0.01% 769
2021
Q4 		$1K Buy
+154
New +$2.4K ﹤0.01% 835

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Tyler-Stone Wealth Management's AVIR Position: Q4 2022 in Review

Tyler-Stone Wealth Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2022, closing a stake of 154 shares — an estimated $1K sold.

Tyler-Stone Wealth Management first reported a position in AVIR in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2022. 131 funds tracked by Wall St. Rank hold AVIR as of Q4 2022.

  • Tyler-Stone Wealth Management reported no remaining Atea Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Tyler-Stone Wealth Management sold 154 Atea Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Tyler-Stone Wealth Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Tyler-Stone Wealth Management's Atea Pharmaceuticals position peaked at $1K in Q3 2022.
  • 131 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2022.

Based on Tyler-Stone Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.